|
KMID : 1191420110100010012
|
|
Korean Journal of Optometry and Vision Science
2011 Volume.10 No. 1 p.12 ~ p.22
|
|
|
Comparison of Intravitreal Injection of Triamcinolone and Bevacizumab and Recurrence of Macular Edema with RVO
|
|
Jang Hyun-Duk
Lee Soo-Jung
Park Jung-Min
|
|
|
Abstract
|
|
|
Purpose: To compare the effect of single intravitreal injection of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, with that of triamcinolone acetonide, a corticosteroid for reduction of macular edema (ME) with retinal vein occlusion and to analyze predisposing factors for recurrence of macular edema.
Methods: 116 eyes with macular edema from retinal vein occlusion were enrolled. Single intravitreal injection of 4 mg/0.1 mL triamcinolone (Triamcinolone group) or bevacizumab 1.25 mg/0.05 mL (Bevacizumab group) was done. The clinical course of best-corrected visual acuity (BCVA) worth a logarithm of the minimum angle of resolution chart (LogMAR), intraocular pressure (IOP), averaged central macular thickness (CMT), total macular volume and predisposing factor for recurrence.
Results: The bevacizumab injected group with BRVO showed significant improvement of best corrected visual acuity up to six months after the injection. The mean postoperative IOP was significantly increased in triamcinolone injected group. In triamcinolone injected group for ischemic-CRVO, that was significantly increased than Beavacizumab injected group. CMT was significantly reduced in early period of Bevacizumab injected group than triamcinolone injected group. Baseline BCVA was the only predisposing factor of recurrence in Bevacizumab injection for BRVO and duration of retinal vein occlusion to treatment was the one in Bevacizumab injection for CRVO.
Conclusions: Bevacizumab injection was better than triamcinolone injection for reducing the central macular thickness in early period of BRVO groups. BRVO patients who benefit from Bevacizumab were significantly good BCVA at baseline than patients with persisting ME. In CRVO patients who benefit from Bevacizumab were significantly early treatment than patients with persisting ME.
|
|
|
KEYWORD
|
|
|
Bevacizumab, Macular edema, Retinal vein occlusion, Triamcinolone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|